Stemline Therapeutics Company Profile (NASDAQ:STML)

About Stemline Therapeutics

Stemline Therapeutics logoStemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: STML
  • CUSIP:
Key Metrics:
  • Previous Close: $6.65
  • 50 Day Moving Average: $9.33
  • 200 Day Moving Average: $10.46
  • 52-Week Range: $3.88 - $14.60
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.15
  • P/E Growth: 0.00
  • Market Cap: $115.11M
  • Outstanding Shares: 17,846,000
  • Beta: 0.13
Profitability:
  • Net Margins: -4,058.44%
  • Return on Equity: -50.06%
  • Return on Assets: -44.60%
Debt:
  • Current Ratio: 5.60%
  • Quick Ratio: 5.60%
Additional Links:
Companies Related to Stemline Therapeutics:

Analyst Ratings

Consensus Ratings for Stemline Therapeutics (NASDAQ:STML) (?)
Ratings Breakdown: 7 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $23.25 (260.47% upside)

Analysts' Ratings History for Stemline Therapeutics (NASDAQ:STML)
Show:
DateFirmActionRatingPrice TargetDetails
2/6/2017Ladenburg Thalmann Financial ServicesReiterated RatingBuyView Rating Details
2/6/2017WedbushLower Price TargetOutperform$19.00 -> $11.00View Rating Details
2/2/2017Cowen and CompanyReiterated RatingBuyView Rating Details
2/3/2017Jefferies Group LLCSet Price TargetBuy$16.00View Rating Details
1/8/2017HC WainwrightSet Price TargetBuy$34.00View Rating Details
12/7/2016Roth CapitalReiterated RatingBuy$32.00View Rating Details
3/18/2016Rodman & RenshawReiterated RatingBuyView Rating Details
(Data available from 2/24/2015 forward)

Earnings

Earnings History for Stemline Therapeutics (NASDAQ:STML)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2017        
5/9/2016Q116($0.59)($0.51)$121.43 million$205.65 millionViewN/AView Earnings Details
3/14/2016Q4($0.57)($0.58)ViewN/AView Earnings Details
11/6/2015Q315($0.59)($0.53)ViewN/AView Earnings Details
8/10/2015Q2($0.41)($0.58)ViewN/AView Earnings Details
5/11/2015Q1($0.45)($0.46)ViewN/AView Earnings Details
3/13/2015($0.60)($0.53)ViewN/AView Earnings Details
11/12/2014Q314($0.58)($0.53)ViewN/AView Earnings Details
8/14/2014($0.71)($0.47)ViewN/AView Earnings Details
5/22/2014($0.72)($0.70)$0.07 million$0.07 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Stemline Therapeutics (NASDAQ:STML)
Current Year EPS Consensus Estimate: $-2.14 EPS
Next Year EPS Consensus Estimate: $-2.05 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.59)($0.55)($0.57)
Q2 20163($0.56)($0.49)($0.53)
Q3 20163($0.61)($0.54)($0.57)
Q4 20163($0.67)($0.54)($0.59)
Q1 20171($0.42)($0.42)($0.42)
Q2 20171($0.41)($0.41)($0.41)
Q3 20171($0.40)($0.40)($0.40)
Q4 20171($0.54)($0.54)($0.54)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Stemline Therapeutics (NASDAQ:STML)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Stemline Therapeutics (NASDAQ:STML)
Insider Ownership Percentage: 16.70%
Institutional Ownership Percentage: 37.76%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/16/2017Ivan BergsteinCEOSell3,652$6.42$23,445.84View SEC Filing  
2/16/2017Kenneth HobermanCOOSell1,508$6.42$9,681.36View SEC Filing  
1/19/2017David GioncoInsiderSell3,593$11.46$41,175.78View SEC Filing  
1/10/2017Kenneth HobermanCOOSell9,110$13.82$125,900.20View SEC Filing  
3/8/2016David GioncoCAOSell1,148$5.32$6,107.36View SEC Filing  
3/8/2016Ivan BergsteinCEOSell5,537$5.34$29,567.58View SEC Filing  
3/8/2016Kenneth HobermanCOOSell2,412$5.34$12,880.08View SEC Filing  
2/17/2016Ivan BergsteinCEOSell3,244$4.46$14,468.24View SEC Filing  
2/17/2016Kenneth HobermanCOOSell1,503$4.54$6,823.62View SEC Filing  
1/20/2016David GioncoCAOSell3,217$4.82$15,505.94View SEC Filing  
11/30/2015Ivan BergsteinCEOSell12,235$8.20$100,327.00View SEC Filing  
4/27/2015Eric K RowinskyInsiderSell10,824$15.77$170,694.48View SEC Filing  
3/19/2015Kenneth HobermanCOOSell17,307$16.43$284,354.01View SEC Filing  
1/20/2015David GioncoCAOSell3,311$14.22$47,082.42View SEC Filing  
11/26/2014Ivan BergsteinCEOSell11,974$14.40$172,425.60View SEC Filing  
9/3/2014Ivan BergsteinCEOBuy2,000$11.05$22,100.00View SEC Filing  
9/2/2014Kenneth HobermanCOOBuy2,000$10.99$21,980.00View SEC Filing  
9/2/2014Kenneth J ZuerblisDirectorBuy1,000$11.14$11,140.00View SEC Filing  
5/30/2013Kenneth J ZuerblisDirectorBuy3,000$16.01$48,030.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Stemline Therapeutics (NASDAQ:STML)
DateHeadline
News IconTrading Scope: Watching Shares of Stemline Therapeutics Inc (STML) - Baxter Review (NASDAQ:STML)
baxternewsreview.com - February 23 at 8:15 PM
News IconWatching the Levels: Stemline Therapeutics, Inc. (NASDAQ:STML) - BVN (NASDAQ:STML)
bvnewsjournal.com - February 23 at 8:15 PM
openpr.com logoStemline Therapeutics Inc (NASDAQ:STML) Investor Lawsuit alleges False and Misleading Statements (NASDAQ:STML)
www.openpr.com - February 22 at 8:16 PM
News IconSignal Watch: Checking the Numbers for Stemline Therapeutics Inc (STML) - Davidson Register (NASDAQ:STML)
davidsonregister.com - February 22 at 10:07 AM
finance.yahoo.com logoSHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Stemline ... - Yahoo Finance (NASDAQ:STML)
finance.yahoo.com - February 22 at 10:07 AM
streetinsider.com logoStemline Therapeutics (STML) Offers Update on Clinical Programs - StreetInsider.com (NASDAQ:STML)
www.streetinsider.com - February 22 at 10:07 AM
us.rd.yahoo.com logoStemline Therapeutics Provides Update on Clinical Programs (NASDAQ:STML)
us.rd.yahoo.com - February 21 at 4:52 PM
us.rd.yahoo.com logo7:05 am Stemline Therapeutics provides update on its SL-401, SL-801, and SL-701 clinical programs (NASDAQ:STML)
us.rd.yahoo.com - February 21 at 4:52 PM
us.rd.yahoo.com logoSHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Stemline Therapeutics, Inc. (STML) and Lead Plaintiff Deadline - April 4, 2017 (NASDAQ:STML)
us.rd.yahoo.com - February 21 at 4:52 PM
us.rd.yahoo.com logoIMPORTANT SHAREHOLDER NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:STML)
us.rd.yahoo.com - February 21 at 4:52 PM
feeds.benzinga.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Filed a Complaint to Recover Losses Suffered by Investors in Stemline Therapeutics, Inc. (NASDAQ:STML)
feeds.benzinga.com - February 21 at 12:45 PM
News IconAnalysts Have Spoken & Consensus Is in for Stemline Therapeutics, Inc. (NASDAQ:STML) - Rockville Register (NASDAQ:STML)
rockvilleregister.com - February 20 at 7:09 PM
News IconStemline Therapeutics Inc STML Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:STML)
www.bioportfolio.com - February 18 at 7:02 PM
News IconWatching the Technicals: Stemline Therapeutics Inc. (STML) - Benton Bulletin (NASDAQ:STML)
bentonbulletin.com - February 18 at 8:54 AM
4-traders.com logoLundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc., and Encourages Investors with Losses to Contact the Firm (NASDAQ:STML)
www.4-traders.com - February 17 at 7:19 PM
businesswire.com logoBragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Stemline Therapeutics, Inc. (STML) and Encourages Investors with Losses to ... (NASDAQ:STML)
www.businesswire.com - February 17 at 7:19 PM
us.rd.yahoo.com logoBragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Stemline Therapeutics, Inc. (STML) and Encourages Investors with Losses to Contact the Firm (NASDAQ:STML)
us.rd.yahoo.com - February 17 at 7:19 PM
4-traders.com logoSTEMLINE STML ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Investigates Stemline Therapeutics, Inc.; Encourages Investors to Contact... (NASDAQ:STML)
www.4-traders.com - February 16 at 7:50 PM
us.rd.yahoo.com logoStemline Investor Loss Alert: Hagens Berman Alerts Investors in Stemline Therapeutics to Expanded Class Period and Reminds Them of Lead Plaintiff Deadline (NASDAQ:STML)
us.rd.yahoo.com - February 16 at 7:50 PM
us.rd.yahoo.com logoEXPANDED CLASS PERIOD: Levi & Korsinsky, LLP Files Complaint to Recover Losses Suffered by Investors in Stemline Therapeutics, Inc. Lead Plaintiff Deadline of April 4, 2017 - STML (NASDAQ:STML)
us.rd.yahoo.com - February 16 at 7:50 PM
businesswire.com logoINVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Stemline Therapeutics, Inc. To Contact Brower Piven Before The ... (NASDAQ:STML)
www.businesswire.com - February 15 at 6:17 AM
4-traders.com logoNewman Ferrara LLP : Announces Corporate Governance Investigation of Stemline Therapeutics Inc. (NASDAQ:STML)
www.4-traders.com - February 15 at 6:17 AM
News IconNASDAQ:STML Investor News: Lawsuit against Stemline Therapeutics Inc seeks to recover losses (NASDAQ:STML)
www.groundreport.com - February 15 at 6:17 AM
us.rd.yahoo.com logoThe Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Stemline Therapeutics, Inc. Investors and Encourages Investors to Contact the Firm (NASDAQ:STML)
us.rd.yahoo.com - February 15 at 6:17 AM
us.rd.yahoo.com logoNewman Ferrara LLP Announces Corporate Governance Investigation of Stemline Therapeutics Inc. (NASDAQ:STML)
us.rd.yahoo.com - February 15 at 6:17 AM
us.rd.yahoo.com logoINVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Stemline Therapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit (NASDAQ:STML)
us.rd.yahoo.com - February 15 at 6:17 AM
News IconVolatile Stock Causing a Fracas Mid-Session: Stemline Therapeutics, Inc. (NASDAQ:STML) - Aiken Advocate (NASDAQ:STML)
aikenadvocate.com - February 13 at 8:20 PM
einnews.com logogeneral assembly approves 2016 results (NASDAQ:STML)
www.einnews.com - February 12 at 7:56 PM
einnews.com logoLiberals to put One Nation ahead of Nationals in unprecedented election deal (NASDAQ:STML)
uspolitics.einnews.com - February 12 at 1:08 AM
benzinga.com logoSTEMLINE SHAREHOLDER ALERT BY FORMER LOUISIANA... (NASDAQ:STML)
www.benzinga.com - February 11 at 3:57 AM
us.rd.yahoo.com logoGlancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Stemline Therapeutics, Inc. Investors and Encourages Investors to Contact the Firm (NASDAQ:STML)
us.rd.yahoo.com - February 11 at 3:57 AM
us.rd.yahoo.com logoRobbins Geller Rudman & Dowd LLP Files Class Action Suit Against Stemline Therapeutics, Inc. (NASDAQ:STML)
us.rd.yahoo.com - February 11 at 3:57 AM
us.rd.yahoo.com logoSTML LOSS NOTICE: Rosen Law Firm Reminds Stemline Therapeutics, Inc. Investors of Important Deadline in First Class Action Filed by Firm - STML (NASDAQ:STML)
us.rd.yahoo.com - February 11 at 3:57 AM
feeds.benzinga.com logoSTML SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Stemline Therapeutics, Inc. and a Lead Plaintiff Deadline of April 4, 2017 (NASDAQ:STML)
feeds.benzinga.com - February 10 at 12:34 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Stemline Therapeutics, Inc. and Certain Officers – STML (NASDAQ:STML)
finance.yahoo.com - February 9 at 5:28 AM
finance.yahoo.com logoIMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc., and Encourages Investors with Losses to Contact the Firm (NASDAQ:STML)
finance.yahoo.com - February 9 at 5:28 AM
News IconLawsuit for Investors in Stemline Therapeutics Inc (NASDAQ:STML) over Alleged Violations of Securities Laws Filed (NASDAQ:STML)
www.digitaljournal.com - February 8 at 6:22 AM
News IconThe Insider Selling: Stemline Therapeutics, Inc. (STML) COO Sells $125900.20 in Stock (NASDAQ:STML)
prensariotiretail.com - February 8 at 6:22 AM
us.rd.yahoo.com logoSHAREHOLDER ALERT: Class Action Lawsuit Filed Against Stemline Therapeutics, Inc. - STML (NASDAQ:STML)
us.rd.yahoo.com - February 8 at 6:22 AM
us.rd.yahoo.com logoIMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:STML)
us.rd.yahoo.com - February 8 at 6:22 AM
us.rd.yahoo.com logoIMPORTANT NOTICE TO SHAREHOLDERS: Brower Piven Notifies Shareholders of Securities Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Stemline Therapeutics, Inc. (STML) To Contact Brower P (NASDAQ:STML)
us.rd.yahoo.com - February 8 at 6:22 AM
us.rd.yahoo.com logoFederman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Stemline Therapeutics, Inc. (NASDAQ:STML)
us.rd.yahoo.com - February 8 at 6:22 AM
us.rd.yahoo.com logoRobbins Arroyo LLP: Stemline Therapeutics, Inc. (STML) Misled Shareholders According to a Recently Filed Class Action (NASDAQ:STML)
us.rd.yahoo.com - February 8 at 6:22 AM
us.rd.yahoo.com logoIMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc., and Encourages Investors with Losses to Contact the Firm (NASDAQ:STML)
us.rd.yahoo.com - February 8 at 6:22 AM
finance.yahoo.com logoBragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Stemline Therapeutics, Inc. (STML) and Encourages Investors to Contact the Firm (NASDAQ:STML)
finance.yahoo.com - February 8 at 6:22 AM
finance.yahoo.com logoIMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:STML)
finance.yahoo.com - February 8 at 6:22 AM
feeds.benzinga.com logoIMPORTANT STEMLINE THERAPEUTICS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the Southern District of New York against Stemline Therapeutics, Inc. (NASDAQ:STML)
feeds.benzinga.com - February 7 at 5:48 PM
feeds.benzinga.com logoIMPORTANT NOTICE TO SHAREHOLDERS: Brower Piven Notifies Shareholders of Securities Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Stemline Therapeutics, Inc. (STML) To Contact Brower Piven Before Th (NASDAQ:STML)
feeds.benzinga.com - February 7 at 2:55 PM
businesswire.com logoSTML INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Stemline ... - Business Wire (press release) (NASDAQ:STML)
www.businesswire.com - February 7 at 1:14 AM
finance.yahoo.com logoStemline Investor Loss Alert: Hagens Berman Alerts Investors in Stemline Therapeutics to Securities Class Action and ... - Yahoo Finance (NASDAQ:STML)
finance.yahoo.com - February 6 at 8:09 PM

Social

What is Stemline Therapeutics' stock symbol?

Stemline Therapeutics trades on the NASDAQ under the ticker symbol "STML."

Where is Stemline Therapeutics' stock going? Where will Stemline Therapeutics' stock price be in 2017?

7 equities research analysts have issued twelve-month target prices for Stemline Therapeutics' shares. Their predictions range from $11.00 to $34.00. On average, they anticipate Stemline Therapeutics' stock price to reach $23.25 in the next twelve months.

When will Stemline Therapeutics announce their earnings?

Stemline Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.

What are analysts saying about Stemline Therapeutics stock?

Here are some recent quotes from research analysts about Stemline Therapeutics stock:

  • According to Zacks Investment Research, "Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York. " (2/9/2017)

  • Jefferies Group LLC analysts commented, "We had a chance to host investor meetings with mgmt, which primarily focused on near-term SL-401 catalysts. In BPDCN, the focus was around the pot’l 2H16 meeting with FDA to determine the amount of data needed to submit a BLA. The company also presented incrementally updated data in BPDCN that was consistent with data from ASCO." (7/22/2016)

Who owns Stemline Therapeutics stock?

Stemline Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (8.27%), Franklin Resources Inc. (8.12%), Eventide Asset Management LLC (4.77%), State Street Corp (1.41%), J. Goldman & Co LP (1.12%) and Bogle Investment Management L P DE (0.53%). Company insiders that own Stemline Therapeutics stock include David Gionco, Eric K Rowinsky, Ivan Bergstein and Kenneth Hoberman.

Who sold Stemline Therapeutics stock? Who is selling Stemline Therapeutics stock?

Stemline Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Franklin Resources Inc., Dimensional Fund Advisors LP and Paradigm Asset Management Co. LLC. Company insiders that have sold Stemline Therapeutics stock in the last year include David Gionco, Ivan Bergstein and Kenneth Hoberman.

Who bought Stemline Therapeutics stock? Who is buying Stemline Therapeutics stock?

Stemline Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including J. Goldman & Co LP, Bogle Investment Management L P DE, Oxford Asset Management, State Street Corp, Ladenburg Thalmann Financial Services Inc., Perceptive Advisors LLC and Renaissance Technologies LLC.

How do I buy Stemline Therapeutics stock?

Shares of Stemline Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Stemline Therapeutics stock cost?

One share of Stemline Therapeutics stock can currently be purchased for approximately $6.45.

Stemline Therapeutics (NASDAQ:STML) Chart for Friday, February, 24, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Stemline Therapeutics (NASDAQ:STML)

Earnings History Chart

Earnings by Quarter for Stemline Therapeutics (NASDAQ:STML)

Dividend History Chart

Dividend Payments by Quarter for Stemline Therapeutics (NASDAQ:STML)

Last Updated on 2/24/2017 by MarketBeat.com Staff